The Power of Vascular Innovation
WATCH NOW
Groundbreaking technology
Our unique process, paired with innovation and continued improvement and evolution, puts us at the forefront.
Humacyte CEO Dr. Laura Niklason Presents
at J.P. Morgan Healthcare Conference

Entrepreneurial Journey
Oh, the Places Grads Go
Surgeons Perform First Bioengineered Blood Vessel Transplant in Military Patient
Why Human Acellular Vessels (HAV)?
From lower costs to fewer operations, HAVs may offer critical benefits.